AN2 Therapeutics, Inc. financial data

Symbol
ANTX on Nasdaq
Location
Menlo Park, CA
Fiscal year end
31 December
Latest financial report
17 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 12% % 11%
Return On Equity -55% % -1.5%
Return On Assets -49% % -0.41%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 35,941,195 shares 19%
Common Stock, Shares, Outstanding 27,413,171 shares -8.4%
Entity Public Float $23,078,812 USD -44%
Weighted Average Number of Shares Outstanding, Basic 30,215,747 shares 1.3%
Weighted Average Number of Shares Outstanding, Diluted 30,215,747 shares 1.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $24,769,000 USD -39%
General and Administrative Expense $13,340,000 USD -5.2%
Operating Income (Loss) $38,109,000 USD 33%
Net Income (Loss) Attributable to Parent $35,174,000 USD 31%
Earnings Per Share, Basic -1.16 USD/shares 33%
Earnings Per Share, Diluted -1.16 USD/shares 33%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $19,941,000 USD -6.6%
Assets, Current $59,937,000 USD -31%
Other Assets, Noncurrent $0 USD -100%
Assets $61,950,000 USD -33%
Accounts Payable, Current $3,021,000 USD -8.9%
Employee-related Liabilities, Current $2,418,000 USD 44%
Accrued Liabilities, Current $2,052,000 USD -54%
Liabilities, Current $8,720,000 USD -15%
Other Liabilities, Noncurrent $170,000 USD
Liabilities $8,890,000 USD -13%
Accumulated Other Comprehensive Income (Loss), Net of Tax $57,000 USD 84%
Retained Earnings (Accumulated Deficit) $240,950,000 USD -17%
Stockholders' Equity Attributable to Parent $53,060,000 USD -35%
Liabilities and Equity $61,950,000 USD -33%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $10,624,000 USD 40%
Net Cash Provided by (Used in) Financing Activities $65,000 USD -81%
Net Cash Provided by (Used in) Investing Activities $9,193,000 USD -65%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 27,413,171 shares -8.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,366,000 USD -115%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $19,941,000 USD -6.6%
Deferred Tax Assets, Valuation Allowance $55,746,000 USD -4.1%
Deferred Tax Assets, Gross $55,746,000 USD -4.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $35,148,000 USD 32%
Deferred Tax Assets, Operating Loss Carryforwards $28,809,000 USD 0.44%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $10,532,000 USD 406%
Additional Paid in Capital $293,953,000 USD 2.2%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $6,246,000 USD -25%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%